Filter Results:
(124)
Show Results For
- All HBS Web (124)
- Faculty Publications (45)
Show Results For
- All HBS Web (124)
- Faculty Publications (45)
Page 1 of 124
Results →
- March 2017
- Case
Cantel Medical
By: John R. Wells and Gabriel Ellsworth
Cantel Medical Corporation provided infection prevention and control products and services for patients, caregivers, and other healthcare providers. In 2016, Cantel generated sales of $665 million and net profits of $60 million, double the levels of five years earlier.... View Details
Keywords: Cantel; Charles Diker; Furniture Industry; Matrix Organization; Acquisition; Mergers and Acquisitions; Business Conglomerates; Business Units; Business Growth and Maturation; Business Organization; For-Profit Firms; Chemicals; Profit; Revenue; Geographic Scope; Multinational Firms and Management; Health; Health Care and Treatment; Business History; Business or Company Management; Goals and Objectives; Growth and Development Strategy; Organizational Structure; Problems and Challenges; Research and Development; Opportunities; Strategy; Adaptation; Business Strategy; Competitive Strategy; Corporate Strategy; Diversification; Expansion; Information Technology; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; United States; New Jersey
Wells, John R., and Gabriel Ellsworth. "Cantel Medical." Harvard Business School Case 717-482, March 2017.
- October 2013 (Revised January 2014)
- Supplement
Fred Khosravi and AccessClosure (B)
By: Richard G. Hamermesh and Lauren Barley
It was January 2013, and Fred Khosravi, chairman of the board of AccessClosure Inc., wondered what the new year had in store for him and AccessClosure, the company he founded in late 2002. Khosravi was cautiously optimistic—the Mountain View, California-based medical... View Details
Keywords: Medical Devices; Vascular Closure Device; Patent Litigation; Patenting; Biomedical Research; Biotechnology; Biotech; Technological Innovation; Patents; Health Care and Treatment; Biotechnology Industry; United States; California
Hamermesh, Richard G., and Lauren Barley. "Fred Khosravi and AccessClosure (B)." Harvard Business School Supplement 814-038, October 2013. (Revised January 2014.)
- March 2006
- Teaching Note
Stan Lapidus: Profile of a Medical Entrepreneur (TN)
By: Robert F. Higgins, Richard G. Hamermesh and Erin Seefeld
Teaching Note to (805-087). View Details
- January 2014
- Supplement
Fred Khosravi and AccessClosure (C)
By: Richard Hamermesh and Lauren Barley
On September 11, 2013, the three-judge panel of the U.S. Court of Appeals for the Federal Circuit denied St. Jude's request to rehear an appeal on the "double patenting" ruling for the '439 patent. Further, it removed the injunction threat that was hanging over the... View Details
Keywords: Medical Devices; Vascular Closure Device; Patent Litigation; Patenting; Biomedical Research; Biotechnology; Biotech; Technological Innovation; Patents; Health Care and Treatment; Biotechnology Industry; United States
Hamermesh, Richard, and Lauren Barley. "Fred Khosravi and AccessClosure (C)." Harvard Business School Supplement 814-074, January 2014.
- January 2014 (Revised June 2015)
- Teaching Note
Amgen Inc: Pursuing Innovation and Imitation? (A), (B)
By: Ian Mackenzie
- 15 Apr 2014
- News
Bertarelli Foundation Gift Names Deans' Health & Life Sciences Challenge Prize
Life Sciences Challenge, launched in 2012 and chaired by Dean Nohria and Dr. Jeffrey S. Flier, dean of the Faculty of Medicine, Harvard Medical School. In recognition of the donor's generosity, the Deans' Challenge prize will be named the... View Details
- February 2006 (Revised August 2006)
- Case
deCODE Genetics: Hunting for Genes to Develop Drugs
By: Debora L. Spar
In 1996, Kari Stefansson launched a new kind of biotechnology company and a whole new way of attacking diseases. Based in Iceland, his firm, deCODE Genetics, plans to identify the individual genetic markers that lead to society's most prevalent diseases. To do so, it... View Details
Keywords: Information; Innovation Strategy; Genetics; Ethics; Health Disorders; Biotechnology Industry; Iceland
Spar, Debora L., and Chris Bebenek. "deCODE Genetics: Hunting for Genes to Develop Drugs." Harvard Business School Case 706-040, February 2006. (Revised August 2006.)
- January 2011 (Revised January 2012)
- Supplement
The Case of the Unidentified Healthcare Companies2010 (CW)
By: Richard M.J. Bohmer, Ethan S Bernstein, Margarita Krivitski and Srinidhi Reddy
This case presents financial statements and selected rations for 14 unidentified healthcare organizations and asks that each set of financial information be matched with one of the following healthcare companies: a biotechnology firm, a community nursing company, a... View Details
- January 2011 (Revised January 2012)
- Case
The Case of the Unidentified Healthcare Companies2010
By: Richard Bohmer, Ethan Bernstein, Margarita Krivitski and Srinidhi Reddy
This case presents financial statements and selected ratios for 14 unidentified healthcare organizations and asks that each set of financial information be matched with one of the following healthcare companies: a biotechnology firm, a community nursing company, a... View Details
Bohmer, Richard, Ethan Bernstein, Margarita Krivitski, and Srinidhi Reddy. "The Case of the Unidentified Healthcare Companies2010." Harvard Business School Case 611-043, January 2011. (Revised January 2012.)
- 13 Jan 2003
- Research & Ideas
Making Biotech Work as a Business
for example, was a banner year for bad news, with thirty late-stage clinical failures of biotech drugs, he said. The online magazine Signals, which is published by Recombinant Capital, a consulting firm that works on biotechnology... View Details
Gary P. Pisano
Gary Pisano is the Harry E. Figgie, Jr. Professor of Business Administration at the Harvard Business School where he has been on the faculty since 1988. From 2018-2023, Pisano was Harvard Business School’s Senior Associate Dean for Faculty Promotion and... View Details
- July–August 2021
- Article
Lowering the Bar? External Conditions, Opportunity Costs, and High-Tech Startup Outcomes
By: Annamaria Conti and Maria P. Roche
We assess the heterogeneous impact of economic downturns on individuals’ decisions to bring high-technology ideas to the market in the form of new ventures. We thereby examine how worsening labor market conditions influence individuals’ opportunity costs of starting... View Details
Keywords: Necessity Entrepreneurship; Economic Conditions; Recessions; High-tech Startups; Opportunity Costs; Entrepreneurship; Economic Slowdown and Stagnation; Business Startups; Information Technology; Performance; Labor
Conti, Annamaria, and Maria P. Roche. "Lowering the Bar? External Conditions, Opportunity Costs, and High-Tech Startup Outcomes." Organization Science 32, no. 4 (July–August 2021): 965–986.
- Person Page
Press / Media
By: Gary P. Pisano
Thought Leader: Gary Pisano
by Amy Bernstein, strategy+business, Summer 2007
A leading student of the biotech business describes the problems holding the industry back, and how it can overcome... View Details
- 09 Oct 2020
- Blog Post
4 Things To Know About the MS/MBA Biotech
myself, did come from a biotechnology company, but there were also people from life sciences consulting firms, research laboratories, medical device companies and larger pharmaceutical companies. This... View Details
- June 2005 (Revised July 2006)
- Background Note
Note on the Convergence Between Genomics & Information Technology
By: David B. Yoffie, Dharmesh M Mehta and Rachel Sha
Focuses on the convergence between the genomics and semiconductor industries, in particular organ printing, DNA computing, biomolecular sensory networks, and DNA microarrays. Explains what this newly converged world looks like based on current research and findings in... View Details
Keywords: Genetics; Information Technology; Business Model; Disruptive Innovation; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry; Biotechnology Industry
Yoffie, David B., Dharmesh M Mehta, and Rachel Sha. "Note on the Convergence Between Genomics & Information Technology." Harvard Business School Background Note 705-500, June 2005. (Revised July 2006.)
- September 2014
- Case
Pfizer's Centers for Therapeutic Innovation (CTI)
By: Gary Pisano, James Weber and Kait Szydlowski
In 2010, Pfizer established four small research units in New York, Boston, San Francisco, and San Diego located close to several premier Academic Medical Centers (AMCs), or hospitals with adjoining medical schools. The goal of these units was to redesign collaboration... View Details
Keywords: Drug Development; Academic Collaboration; Research And Development; Innovation; Translational Research; Management; Operations; Problems and Challenges; Research; Science; Information Technology; Strategy; Biotechnology Industry; Biotechnology Industry; North and Central America; Europe; Asia
Pisano, Gary, James Weber, and Kait Szydlowski. "Pfizer's Centers for Therapeutic Innovation (CTI)." Harvard Business School Case 615-024, September 2014.
- April 1993 (Revised October 1995)
- Case
ALZA and Bio-Electro Systems (A): Technological and Financial Innovation
By: Josh Lerner and Peter Tufano
To develop the next generation of risky products, ALZA, a mature and profitable biotechnology firm specializing in drug delivery systems, must raise $40 million. Organizational constraints and competitive concerns demand that the work be done inside the firm. However,... View Details
Keywords: Risk and Uncertainty; Technological Innovation; Business Subsidiaries; Decision Choices and Conditions; Corporate Finance; Biotechnology Industry; Biotechnology Industry
Lerner, Josh, and Peter Tufano. "ALZA and Bio-Electro Systems (A): Technological and Financial Innovation." Harvard Business School Case 293-124, April 1993. (Revised October 1995.)
- December 1999 (Revised August 2001)
- Case
Millennium Pharmaceuticals, Inc. (A)
By: Stefan H. Thomke and Ashok Nimgade
Focuses on Millennium's strategy to grow and revolutionize drug development through the use of new technologies such as genomics. Describes how Millennium Pharmaceuticals--a fast-growing biotechnology firm in Cambridge, MA--has used strategic alliances to finance the... View Details
Keywords: Cost Management; Financing and Loans; Medical Specialties; Retention; Growth and Development Strategy; Time Management; Product Development; Problems and Challenges; Alliances; Technology; Biotechnology Industry; Biotechnology Industry; Cambridge
Thomke, Stefan H., and Ashok Nimgade. "Millennium Pharmaceuticals, Inc. (A)." Harvard Business School Case 600-038, December 1999. (Revised August 2001.)
- 22 Apr 2009
- Working Paper Summaries